Grantham, Mayo, Van Otterloo & Co (GMO)’s ResMed RMD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.26M	Buy	+5,721	New	+$1.25M	﹤0.01%	507
2026 Q2	–	Sell	-18,923	Closed	-$4.25M	–	712
2026 Q1	$4.25M	Buy	+18,923	New	+$4.72M	0.01%	345
2016 Q1	–	Sell	-37,303	Closed	-$2M	–	620
2015 Q4	$2M	Sell	37,303 -35,200	-49%	-$1.98M	0.01%	336
2015 Q3	$3.7M	Sell	72,503 -37,400	-34%	-$2.01M	0.01%	271
2015 Q2	$6.2M	Sell	109,903 -800	-0.7%	-$50.5K	0.02%	232
2015 Q1	$7.95M	Sell	110,703 -200	-0.2%	-$13K	0.02%	214
2014 Q4	$6.22M	Sell	110,903 -23,811	-18%	-$1.24M	0.02%	237
2014 Q3	$6.64M	Sell	134,714 -40,600	-23%	-$2.07M	0.02%	243
2014 Q2	$8.88M	Buy	175,314 +4,500	+3%	+$223K	0.02%	210
2014 Q1	$7.63M	Buy	170,814 +84,343	+98%	+$3.79M	0.02%	232
2013 Q4	$4.07M	Sell	86,471 -329	-0.4%	-$16.7K	0.01%	341
2013 Q3	$4.58M	Buy	86,800 +24,458	+39%	+$1.19M	0.01%	322
2013 Q2	$2.81M	Buy	+62,342	New	+$2.96M	0.01%	367

Other funds holding RMD

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RMD Position: Q3 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in ResMed (RMD) in Q3 2026: 5,721 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #507 among its holdings. This is a return to the name: Grantham, Mayo, Van Otterloo & Co (GMO) previously reported a position in RMD as recently as Q1 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RMD in Q2 2013 and has held it in 13 quarters since. The position peaked at $8.88M in Q2 2014. 741 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 5,721 shares of ResMed worth $1.26M as of Q3 2026.
ResMed was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q3 2026.
ResMed made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q3 2026, its #507 holding.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ResMed in Q2 2013 and has held it in 13 quarters since.
Grantham, Mayo, Van Otterloo & Co (GMO)'s ResMed position peaked at $8.88M in Q2 2014.
741 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2026, filed 13 Nov 2026.